Heart failure event definitions in drug trials in patients with type 2 diabetes

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 4, 2016, Pages 294-296

  Sharma, Abhinav ^a,b   Bhatt, Deepak L ^c,d   Calvo, Gonzalo ^e   Brown, Nancy J ^f   Zannad, Faiez ^g   Mentz, Robert J ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Ctr Hospitalier Univ de Nancy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; SAXAGLIPTIN; TROPONIN; ANTIDIABETIC AGENT;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DIABETIC PATIENT; DISEASE EXACERBATION; DYSPNEA; ECHOCARDIOGRAPHY; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT CARE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFERENCE VALUE; SYMPTOM; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; STANDARDS;

DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC;

EID: 84962808581     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)00049-8     Document Type: Note

References (12)

1. Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes Dec, 2008, FDA, US Food and Drug Administration, Silver Spring, MD, (accessed Sept 1, 2015). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf.
2. McMurray JJV, Gerstein HC, Holman RR, Pfeller MA Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014, 2:843-851.
3. Cavender MA, Steg PG, Smith SC, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 2015, 132:923-931.
4. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326.
5. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014, 130:1579-1588.
6. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 2011, 162:818-825.
7. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015, 3:356-366.
8. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials. J Am Coll Cardiol 2015, 66:403-469.
9. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
10. Rydén L, Thráinsdóttir I, Swedberg K Adjudication of serious heart failure in patients from PROactive. Lancet 2007, 369:189-190.
11. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure. Circulation 2013, 128:e240-e327.
12. Zannad F, Stough WG, Pitt B, et al. Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J 2008, 29:413-421.